Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Additional Reading from MarketBeat
The “Duck Stock” Keeps Quietly Making Money for ShareholdersBy Peter Frank. Published: 6/11/2026. 
Key Points
- Aflac generates steady cash flow through supplemental insurance and long-standing market positions in the U.S. and Japan.
- Share buybacks and dividend increases continue to support per-share earnings growth and shareholder returns.
- The stock offers stability and income, though analysts see limited near-term upside from current prices.
- Special Report: Elon Musk: This Could Turn $100 into $100,000
Insurance stocks can be volatile plays, with earnings affected by floods, wildfires, interest rates, and claims inflation. And then there’s Aflac (NYSE: AFL). This conservative insurer helps investors sleep at night by generating steady cash, hiking its dividend, buying back stock, and delivering long-term appreciation. In fact, Aflac has raised its dividend for 44 consecutive years, and after a strong first quarter in 2026, the company shows no signs of stopping.
The SpaceX IPO is drawing near, but the real opportunity may lie in 5 lesser-known companies providing the critical infrastructure SpaceX depends on to operate.
Goldman Sachs and Morgan Stanley are reportedly already building positions in one of these names. Another is a resource miner that Elon Musk's broader empire - including Tesla - relies on. Lance Ippolito has detailed all five inside his free SpaceX Investing Blackbook. Download the free SpaceX Investing Blackbook before these names go mainstream
The question is whether the stock’s well-earned reputation is already baked into the price, or whether there is still enough upside for new buyers. For retail investors who prefer reliability over excitement, Aflac might be the duck that quacks income. How Aflac Makes Its MoneyMany investors know the Columbus, Georgia-based insurer best from its TV commercials featuring a quacking duck. Fewer may understand how the company actually makes money. The company does sell life insurance and disability insurance, but it is better known as a supplemental insurance provider. That means it sells policies that pay cash directly to policyholders when they experience a covered illness or injury. The business model is simple. When a cancer diagnosis or accident forces someone out of work, Aflac’s cash benefits help cover everyday expenses such as mortgage payments, groceries, or utility bills—costs that a standard health insurance policy doesn’t touch. That niche has made Aflac a dominant force in two different markets. In the United States, the company sells its supplemental plans primarily through employers, building long-term relationships with businesses. In Japan, where Aflac has operated since 1974, the company holds a commanding position in cancer insurance and medical indemnity products. Indeed, half of Aflac’s business comes from Japan, where its brand recognition rivals that of the largest domestic insurers. Earnings Remain Steady Beneath the HeadlinesWhile Aflac’s first-quarter earnings may appear dramatic on the surface, the underlying picture is steadier. On an unadjusted basis, net earnings jumped to $1 billion, or $1.98 per diluted share. That compared with just $29 million, or 5 cents per diluted share, in the same period a year ago, when the company suffered net investment losses of $963 million, or $1.76 per diluted share. In contrast, this year’s first three months delivered investment gains of $49 million, or 10 cents a share. Adjusted earnings, which exclude investment returns, tell a more modest but still solid story. Adjusted earnings came in at $901 million for the quarter, essentially flat with the $906 million from a year earlier. Adjusted earnings per diluted share rose 5.4% to $1.75, thanks largely to a shrinking share count as the company continued buying back its stock. Japan and the U.S. Continue Driving GrowthAflac’s two dominant markets also tell a more nuanced story. In Japan, pretax adjusted earnings rose 5.1% in dollar terms to $759 million, on net earned premiums of $1.57 billion. In Japanese yen terms, net earned premiums were down 4% year over year. At the same time, new annualized premium sales for the quarter climbed 25.5%, driven by recent health-related products designed for younger Japanese consumers. In the United States, net earned premiums grew 3.5% to $1.56 billion, while pretax adjusted earnings edged up 1.4% to $363 million. Again, these are not exciting numbers, but they reflect the steady growth investors have come to expect. For all of 2025, Aflac reported adjusted earnings of $4 billion, or $7.49 per diluted share, a modest decline from $4.1 billion in 2024 in absolute terms. But with stock buybacks, it was still an improvement on a per-share basis. Shareholder Returns Remain a PriorityBuybacks and dividends remain central to Aflac’s strategy, with no signs of slowing. The company set its quarterly dividend at 61 cents per share in the first quarter after a 5.2% increase. It also said it returned $1.3 billion to shareholders during the quarter alone, including $1 billion in share repurchases and $315 million in dividends. This type of consistency has kept the stock fairly well valued. Shares are up more than 10% over the past 12 months and up about 5% this year. Over five years, the stock has doubled. With a P/E ratio of about 13 and a dividend yield slightly above 2%, the company’s steady performance and payouts are clear. As a result, Wall Street analysts are largely split on the stock, with an overall recommendation landing at a Hold rating, suggesting the current price may already reflect much of the company’s quality. In fact, with 12 analysts following the stock, the 12-month price target of $112.27 is basically flat from current levels. Six analysts recommend Hold, four suggest Buy, and two recommend Sell. Aflac Remains a Reliable Income StockAflac is clearly not a stock for investors chasing rapid growth. It is a stock for investors who want to own a piece of a durable, well-managed business that reliably generates cash, increases its dividend, and steadily reduces its share count. The appeal is straightforward. Aflac is one of the more dependable income-generating stocks in the insurance arm of the financial sector, competing against rivals such as MetLife (NYSE: MET) and the Colonial Life unit of Unum Group (NYSE: UNM). There will be some earnings volatility from currency fluctuations and investment results, and the stock will respond accordingly. But for investors who want steadiness over surprise, the duck is still worth considering. The main risk isn’t that the company stumbles. It’s that investors pay a full price for a business the market already understands very well. |
